Today: 21 May 2026
Browse Category

Mergers and Acquisitions 26 December 2025 - 26 January 2026

Beazley share price in focus as Zurich’s bid clock ticks toward Feb. 16 — what London traders watch

Beazley share price in focus as Zurich’s bid clock ticks toward Feb. 16 — what London traders watch

Beazley closed Friday at 1,152 pence, up 3.23%, as Zurich’s 1,280 pence-per-share cash offer remains on the table ahead of a Feb. 16 deadline. Beazley’s board rejected the bid, calling it undervalued. Shares dropped sharply after the rejection but recovered by the close. Investors await any revised offer and Beazley’s results due March 4.
26 January 2026
·
Beazley shares rise again as Zurich bid deadline nears — what to watch when London reopens

Beazley shares rise again as Zurich bid deadline nears — what to watch when London reopens

Beazley shares rose 3.2% to £11.52 on Friday but remain below Zurich’s 1,280p takeover offer, which the board rejected as too low. Zurich faces a Feb. 16 deadline to raise its bid or walk away. Beazley’s board cited a previous 1,315p approach and set March 4 for full-year results. Investors are watching for any revised offer or new bidders.
24 January 2026
···
Kenvue (KVUE) stock price barely budges as Kimberly-Clark deal vote nears

Kenvue (KVUE) stock price barely budges as Kimberly-Clark deal vote nears

Kenvue shares rose 0.1% to $17.77 Friday as investors await a Jan. 29 shareholder vote on its proposed sale to Kimberly-Clark. The deal would give Kenvue holders $3.50 in cash and 0.14625 Kimberly-Clark shares per Kenvue share. Institutional Shareholder Services recommended approval but cited litigation risks. Trading volume has surged ahead of the vote.
23 January 2026
···
Netflix flips to an all-cash $82.7 billion Warner Bros. Discovery bid as Paramount clock ticks

Netflix flips to an all-cash $82.7 billion Warner Bros. Discovery bid as Paramount clock ticks

Netflix switched to an all-cash $27.75-per-share bid for Warner Bros. Discovery’s studio and streaming units, keeping the total value at $82.7 billion. The move comes just before Paramount Skydance’s $30-per-share tender offer expires Jan. 21. Warner set a $1.33–$6.86 per-share valuation for the Discovery Global spinoff. Netflix shares rose 1.3% in premarket trading; Warner slipped.
20 January 2026
···
Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue shares rose 0.4% to $17.08 in mid-morning trading after Kimberly-Clark filed new deal documents with U.S. regulators. The stock remains about 5% below the value implied by the pending cash-and-stock takeover. Kenvue shareholders are set to vote on the deal Jan. 29. The transaction’s value fluctuates with Kimberly-Clark’s share price.
14 January 2026
···
Netflix stock slips as all-cash Warner Bros bid talk swirls, with earnings days away

Netflix stock slips as all-cash Warner Bros bid talk swirls, with earnings days away

Netflix shares fell 1.6% Wednesday as investors weighed reports it may switch to an all-cash bid for Warner Bros Discovery’s studio and streaming assets, valued at $82.7 billion. Paramount Skydance, offering $108.4 billion for all of Warner Bros, escalated its challenge with a lawsuit and board nominations. Warner Bros dismissed the lawsuit as meritless. Netflix’s quarterly results are due January 20.
14 January 2026
····
Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol shares rose 2.2% to $148.28 Tuesday, bucking a broader market decline after finalizing its $10.5 billion acquisition of CommScope’s CCS business. Analysts at Barclays, Citi, and Truist raised price targets, citing expected sales growth and stronger demand. The company projects CCS will add $4.1 billion in 2026 sales and $0.15 to EPS, excluding costs. Quarterly earnings are due Jan. 28.
13 January 2026
···
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
D-Wave Quantum stock (QBTS) slides after $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum stock (QBTS) slides after $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum shares fell 3.4% to $30.20 after announcing a $550 million deal to acquire Quantum Circuits, split between $250 million cash and $300 million in stock. The agreement uses a VWAP collar to set share count and requires antitrust and NYSE approval. The deal aims to bring superconducting gate-model systems to market in 2026. Trading volume reached 36.5 million shares.
8 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
US stock market: Vistra stock pops in premarket on $4.7B Cogentrix deal amid AI power-demand boom

US stock market: Vistra stock pops in premarket on $4.7B Cogentrix deal amid AI power-demand boom

Vistra shares rose 4.4% to $170.17 premarket Tuesday after agreeing to buy Cogentrix Energy from Quantum Capital Group in a deal valued at $4.7 billion. The acquisition adds 5.5 gigawatts of natural gas generation across key U.S. markets and is expected to close in mid-to-late 2026. Vistra said the deal should boost per-share cash flow starting in 2027.
6 January 2026
···
BlueScope Steel stock jumps 21% on A$30 takeover bid — the next catalyst investors are watching

BlueScope Steel stock jumps 21% on A$30 takeover bid — the next catalyst investors are watching

BlueScope Steel shares jumped 20.6% to A$29.48 after SGH and Steel Dynamics made a non-binding A$30-per-share takeover offer. The proposal, received Dec. 12, is subject to due diligence, exclusivity, and other conditions. BlueScope’s board is reviewing the bid against its own valuation. The company previously rejected lower offers, citing execution risks.
6 January 2026
···
Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

Uber shares slipped 0.3% to $81.87 after a report said the company has held talks to acquire parking app SpotHero, which was last valued at about $290 million. SpotHero operates in over 400 North American cities. Traders await confirmation of the talks and Uber’s next earnings report, expected Feb. 4. Lyft rose 0.2% while DoorDash fell 0.2% in afternoon trading.
31 December 2025
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Coforge’s $2.35 billion Encora deal tops India’s stocks-to-watch list for Dec. 29

Coforge’s $2.35 billion Encora deal tops India’s stocks-to-watch list for Dec. 29

Coforge agreed to acquire U.S.-based Encora for $2.35 billion and will raise up to $550 million via a share sale to fund the deal. Punjab National Bank reported a 24.34 billion-rupee fraud to regulators. Timex Group India’s promoter plans to sell up to 8.93% on Dec. 29–30. GIFT Nifty futures rose 40 points to 26,100 ahead of Monday’s open.
29 December 2025
··
Ondas Holdings (NASDAQ: ONDS) Stock News Today: Defense-Drone Contracts, M&A Momentum, and Fresh Analyst Targets in a Thin Holiday Market

Ondas Holdings (NASDAQ: ONDS) Stock News Today: Defense-Drone Contracts, M&A Momentum, and Fresh Analyst Targets in a Thin Holiday Market

Ondas Holdings Inc. shares fell about 6% to $8.56 by early afternoon Friday, trading on heavy volume over 24 million shares. The drop comes as small-cap stocks lag in a quiet, post-holiday session, with large-cap and tech indexes little changed. Ondas recently announced a major government contract for an autonomous border-protection drone system, with an initial order expected in January 2026.
26 December 2025
···
1 2 3 4 … 7

Stock Market Today

  • Planet Labs Nears Sustainable Profitability Amid Industry Challenges
    May 21, 2026, 3:12 PM EDT. Planet Labs (PL) operates a vast network of Earth observation satellites capturing global images daily. Despite technological advances and expanded roles in defense and agriculture, the company has yet to secure steady profits due to high costs in satellite manufacturing, launches, maintenance, and R&D. Revenue growth lags behind fixed costs, while long government sales cycles delay cash flow. Management's 2026 guidance shows optimism, focusing on cost control, vertical specialization, and software monetization to enhance margins. Industry peers Rocket Lab (RKLB) and BlackSky Technology (BKSY) face similar profitability challenges. PL's stock has surged 117% year-to-date but trades at a lofty price-to-sales ratio of 31.38, far above the industry average of 3.86, reflecting high investor expectations amid ongoing financial pressures.

Latest articles

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

Nebius Shares Surge 15% After $2.6 Billion AI Power Plan Announced

21 May 2026
Nebius Group N.V. shares surged 15.6% to $221.72 after announcing a fuel cell power deal with Bloom Energy, securing up to 328 MW of on-site electricity capacity for its AI infrastructure. The agreement could cost Nebius up to $2.6 billion over 10 years. Bloom shares rose 12.2% on the news. Nebius's first-quarter revenue jumped to $399 million from $50.9 million a year earlier.
Sirius XM stock nears new highs as traders look at audio strategy

Sirius XM stock nears new highs as traders look at audio strategy

21 May 2026
Sirius XM shares rose 6.8% to $28.90 by 2:07 p.m. EDT Thursday, outpacing major U.S. indexes. The rally followed CFO Zac Coughlin’s investor conference appearance and news of a renewed multi-year NASCAR broadcast deal. First-quarter subscriber losses were smaller than expected, and revenue topped forecasts. Volume reached 4.8 million shares, with a market value near $9.8 billion.
KEEL Surges as Investors Back Keel’s AI Data Center Plans

KEEL Surges as Investors Back Keel’s AI Data Center Plans

21 May 2026
Keel Infrastructure shares jumped 7.1% to $4.53 Thursday, nearing a 52-week high, as investors bet on its pivot from crypto mining to AI-focused power infrastructure. Trading volume reached 22.31 million shares, below average. The company reported a wider net loss of $145.35 million for the March quarter on lower revenue and warned its transformation faces risks tied to permits, costs, and competition.
Go toTop